Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy
This study has been terminated.
Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Information provided by:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier:
NCT00083486
First received: May 24, 2004
Last updated: April 25, 2011
Last verified: April 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine the effectiveness of different doses of epoetin alfa for treating anemia in patients who have cancer; or patients who no longer have any signs of cancer, but remain anemic as a result of their treatment. These patients should not be currently receiving chemotherapy or radiotherapy. A subject's participation in the study will last approximately 6 months. Subjects will receive weekly doses of epoetin alfa or placebo. Their hemoglobin will be tested every week.
| Condition | Intervention | Phase |
|---|---|---|
|
Anemia |
Drug: epoetin alfa |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Treatment |
Resource links provided by NLM:
Further study details as provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Body weight >/=99 lbs
- ECOG 0-2
- Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy
- Screening hemoglobin level of </=11.0 g/dL for men or </=10.0 for women
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00083486
Locations
| United States, Arkansas | |
| Heritage Physician Group-Oncology | |
| Hot Springs, Arkansas, United States, 71913 | |
| United States, Georgia | |
| Spalding Oncology Services | |
| Griffin, Georgia, United States, 30224 | |
| United States, Illinois | |
| Southern Illinois Hematology | |
| Centralia, Illinois, United States, 62801 | |
| United States, Maryland | |
| BioLab Research | |
| Rockville, Maryland, United States, 20852 | |
| United States, New York | |
| Slocum-Dickson Medical Group, PC | |
| New Hartford, New York, United States, 13413 | |
| United States, North Carolina | |
| NorthEast Urology Research | |
| Concord, North Carolina, United States | |
| United States, Ohio | |
| Mid Ohio Oncology Hematology | |
| Columbus, Ohio, United States, 43213 | |
| United States, Pennsylvania | |
| Drexel University College of Medicine | |
| Philadelphia, Pennsylvania, United States, 19102 | |
| United States, South Carolina | |
| Caroline Cancer Center | |
| Aiken, South Carolina, United States, 29403 | |
| Charleston Cancer Care | |
| Charleston, South Carolina, United States, 29406 | |
| Charleston Hematology Oncology | |
| Charleston, South Carolina, United States, 29403 | |
| United States, Tennessee | |
| Volunteer Research Group | |
| Knoxville, Tennessee, United States, 37920 | |
Sponsors and Collaborators
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00083486 History of Changes |
| Other Study ID Numbers: | CR010939, EPO-CAN-203 |
| Study First Received: | May 24, 2004 |
| Last Updated: | April 25, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Anemia Hematologic Diseases Epoetin Alfa Hematinics |
Hematologic Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on June 18, 2013